Genetically engineered mouse (GEM) models of lung tumorigenesis allow careful evaluation of lung tumor initiation, progression, and response to therapy. Using GEM models of oncogene-induced lung cancer, we show the striking similarity of the earliest stages of tumorigenesis induced by KRAS G12D 
Introduction
Lung cancer is the most prevalent malignancy in the industrialized world and was responsible for approximately 160,000 deaths in the United States in 2007 (1) . Despite its prevalence and strikingly high mortality rates, the cellular origins of lung cancer remain obscure and therapeutic approaches to treat the disease have proven disappointingly ineffective (2) . Consequently, the 5-year survival rate for patients with advanced lung cancer remains low, emphasizing the need for new therapeutic approaches to treat this disease.
The genetic heterogeneity of lung cancer has been revealed in more detail and in a manner that has direct implications for therapy (2, 3) . For example, mutational activation of ERBB1, encoding the EGF receptor (EGFR), predicts for a clinical response to EGFR inhibitors such as Tarceva (4, 5) . Similarly, lung cancers expressing an oncogenic EML4-ALK fusion protein respond well to crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK) and MET protein kinases (6) . However, lung cancers expressing mutationally activated KRAS do not respond to either EGFR or ALK inhibitors and, at least with Tarceva, the use of EGFR inhibitors is contraindicated (7) (8) (9) .
Mutationally activated KRAS binds to a multiplicity of effector proteins including (but not limited to) RAF protein kinases, phosphoinositide 3 (PI3) 0 -lipid kinases and RAL-GDS (10, 11) . Consistent with an important role for RAS pathway signaling in lung cancer, mutational activation of BRAF or PIK3CA or silencing of PTEN are detected in a small percentage of lung cancers (12) (13) (14) (15) . Because mutationally activated KRAS remains an intractable pharmacologic target, defining relevant RAS effector pathway(s) in lung cancer is of critical importance as potent and specific inhibitors of RAS effector kinases are being clinically tested for a number of different cancers (11) .
Genetically engineered mouse (GEM) models of KRAS G12D -or BRAF V600E -induced lung cancer have been described (16) (17) (18) (19) . In particular, mice carrying conditionally activated alleles of KRas (KRas LSL ) or BRaf (BRaf CA ), in which oncogene expression is initiated by Cre recombinase at the normal chromosomal locus, have allowed exploration of the earliest events following oncogene activation as well as events involved in cancer progression and metastatic spread (17, 18, (20) (21) (22) . Here, we use KRas LSL and BRaf CA mice to directly compare the effects of oncogenic KRAS G12D or BRAF V600E on benign lung tumorigenesis, malignant cancer progression, and the importance of mitogen-activated protein (MAP)-extracellular signal-regulated kinase (ERK) kinase (MEK)1/2 signaling in tumor maintenance. KRAS G12D -and BRAF V600E -induced benign lung tumors share similar morphologic and histologic characteristics and express markers of alveolar pneumocytes but not Clara cells. Despite the fact that BRAF V600E tumors formed faster and at higher multiplicity, they failed to display malignant progression. In contrast, KRAS G12D -induced lung tumors routinely progressed to higher grade adenocarcinomas. However, both KRAS G12D -and BRAF V600E -induced lung tumors were sensitive to the antitumor effects of MEK1/2 inhibition. Consistent with this, tumor-derived cell lines were growtharrested in vitro following MEK inhibitor treatment, suggesting that MEK1/2 inhibition, either alone or in combination chemotherapy, might represent a viable strategy for targeting KRAS-mutant lung cancers in humans.
Materials and Methods

Mice and adenovirus delivery
All experiments involving mice were conducted in accordance with protocols approved by the University of California, San Francisco Institutional Animal Care and Use Committee. BRaf CA (Braf tm1Mmcm ), KRas LSL (Kras tm4Tyj ), Aqp5 À/À , and LucRep Tg(Actb-GFP-Luc) mice were bred and genotyped as previously described (17, 18, 23, 24) . A stock of adenovirus encoding Cre recombinase (Ad-Cre) was purchased from Viraquest, and intranasal instillation for infection of the mouse lung epithelium was conducted as previously described (25) . BrdU (Sigma) was administered at approximately 30 mg/kg by i.p. injection 20 hours before euthanasia.
Histology and quantification of lung tumor burden
Lungs were removed and fixed in zinc-buffered formalin and stored in 70% (v/v) ethanol before paraffin embedding. Fivemicrometer sections were cut and slides were stained with hematoxylin and eosin (H&E). H&E-stained slides were scanned with an Aperio ScanScope scanner. Quantification was carried out using Aperio Spectrum ImageScope viewing software. Tumor number and size were measured per lung section, and overall tumor burden was calculated as (area of lung section occupied by tumor)/(total area of section) in mm 2 . Differences in lung tumor grade were based on criteria established by Nikitin and colleagues (26) . Statistical significance of differences in lung tumor grade was assessed using the exact Wilcoxon rank-sum test.
For effects of MEK inhibition on tumor prevention, 10 lung lobes from 3 vehicle-treated and 13 lung lobes from 4 PD0325901-treated KRas LSL mice were evaluated. For effects of MEK inhibition on tumor regression, 7 lung lobes from 2 vehicle-treated and 8 lung lobes from 3 PD0325901-treated KRas LSL mice were evaluated.
Drug treatments and bioluminescent imaging PD0325901 (Hansun Trading Co.) was formulated in 0.5% (w/v) (hydroxypropyl)methyl cellulose (HPMT; Sigma) and administered by oral gavage at 12.5 mg/kg per mouse once per day for 5 d/wk. Mice carrying the LucRep transgene were injected with Firefly D-Luciferin (Gold Biotechnology) i.p. and were imaged 10 minutes later using the Xenogen IVIS 100 Bioluminescent Imaging System. Bioluminescent signal measured in photons/s (p/s) was quantified using Live Image software (Caliper Life Sciences).
Immunostaining of mouse lung tissue and immunoblotting
Mouse lungs were fixed in formaldehyde overnight, processed, embedded in paraffin, cut into 5-mm sections, and mounted on glass slides. Citrate-mediated antigen retrieval was conducted, and then the following antibodies were used for detection: anti-SP-C, anti-RAGE, anti-gp38 (Santa Cruz); anti-AQP5 (Calbiochem); anti-BrdU (Roche); anti-Ki67 (Abcam); anti-phospho-ERK1/2 and anti-phospho-S6 (Ser235/236; Cell Signaling Technology).
Cell proliferation was assessed by counting the percentage of surfactant protein (SP-C)-positive tumor cells that were also bromodeoxyuridine (BrdUrd)-positive by double label immunofluorescence. In BRaf CA mice, 6 tumors were analyzed with 9 grids each for a total of 4,112 SP-C-positive cells evaluated. In KRas LSL mice, 5 tumors were analyzed with 9 grids each for a total of 2,831 SP-C-positive cells evaluated. Similar numbers of cells were evaluated for the presence of SP-C/Ki67 double-positive cells in BRAF V600E -versus KRAS
G12D
-induced lung tumors.
Fifty-microgram aliquots of cell extracts were analyzed by standard immunoblotting using antisera against the following proteins: phospho-MEK1/2 (pMEK1/2), phospho-ERK1/2 (pERK1/2), total ERK1/2 (tERK1/2), BIM (Epitomics); cleaved caspase-3 (CC3; Cell Signaling Technology); and cyclin D1 (Cell Signaling Technology). Immunoblots were visualized using the Odyssey Fc System (LI-COR) and ImageStudio Software.
Electron microscopy of BRAF V600E -induced lung tumors Tumor-bearing lungs from initiated BRaf CA/þ mice were removed 11 weeks after Ad-Cre infection and fixed in 2% (v/v) glutaraldehyde, 1%(v/v) paraformaldehyde in 0.1 mol/L sodium cacodylate buffer at pH 7.4. Following fixation, samples were incubated in 2% (v/v) osmium tetroxide in the same buffer. Samples were then stained in 2% (v/v) aqueous uranyl acetate, dehydrated in acetone, infiltrated, and then embedded in LX-112 resin (Ladd Research Industries). Toluidine bluestained semi-thin sections were made to locate the areas of interest. Samples were ultrathin sectioned on a Reichert Ultracut S ultramicrotome and counterstained with 0.8% lead citrate. Grids were examined on a JEOL JEM-1230 (Transmission electron microscope, JEOL USA, Inc.) and photographed with a Gatan UltraScan 1000 digital camera and DigitalMicrograph software (Gatan Inc.).
Lung tumor cell isolation and culture
Lungs of tumor-bearing BRaf CA mice were perfused with dispase (BD Biosciences) and individual lobes were minced and further incubated with dispase and collagenase (Roche). Cell suspensions were then filtered and cultured in Dulbecco's Modified Eagle's Medium (DMEM) with 10% (v/v) normal calf serum. Recombination of the conditional BRaf CA allele was verified using established genotyping protocols (18) . Cell suspensions from lung cancer-bearing KRas LSL mice were obtained in a similar manner and then passaged twice through orthotopic implantation into nude mice before single-cell suspensions were generated and established in culture in DMEM with 10% (v/v) normal calf serum. The cell lines described here have not been separately authenticated using single-nucleotide polymorphism (SNP) or microsatellite DNA markers. Cell proliferation assays were carried out using an Alamar Blue cell viability assay (Invitrogen). PD0325901 was dissolved in dimethyl sulfoxide (DMSO) and applied to cells at a final concentration of 1 mmol/L. Similarly treated cells were permeabilized, stained with propidium iodide, and analyzed by FACScan for DNA content.
Results
BRaf
CA mice display an earlier onset and higher multiplicity of lung tumors than KRas LSL mice
Genetically engineered KRas LSL or BRaf CA mice carry knockin alleles of KRas or Braf, respectively, at the normal chromosomal loci that allow for conditional expression of either oncogenic KRAS G12D or BRAF V600E in response to Cre recombinase (17, 18) . Intranasal instillation of Ad-Cre elicits oncogene expression in the lung epithelium in a manner in which the timing and frequency of oncogene-expressing cells can be investigator-controlled. Lung epithelium expression of KRAS G12D is reported to lead initially to atypical adenomatous hyperplasia (AAH) and then to development of benign lung adenomas and ultimately to emergence of malignant nonsmall cell lung cancers (17) . Lung epithelium expression of BRAF V600E also leads initially to AAH and then to benign lung adenomas but progression to frank malignancy is rare and appears to be constrained by cellular senescence (18 mice at later time points due to the extensive benign tumor burden in the BRaf CA mice, which led to respiratory distress and weight loss such that these mice had to be euthanized. In contrast, at a time when all of the Ad-Cre-treated BRaf CA had been euthanized, all of the similarly treated KRas LSL mice appeared healthy and maintained a normal weight, despite the obvious lung tumor burden that they presented at euthanasia.
BRAF V600E -induced lung tumors fail to progress beyond low-grade, benign adenomas
To better characterize KRAS G12D -or BRAF V600E -induced lung tumors, lesions were classified as epithelial hyperplasia, adenomatous hyperplasia, low-or high-grade adenomas (Fig.  1C ) using criteria established by Nikitin and colleagues (26) . Epithelial hyperplasia was classified as regions of hyperplasia originating from or directly associated with airways. Adenomatous hyperplasia was defined as lesions originating from the alveoli and measuring less than 100 mm in diameter. Adenomas (lesions >100 mm) were classified as being low-or high-grade, depending on the degree of cellular atypia. Percentage of each tumor type per lung section was calculated as area of specific lesion type per area of total lesion area. The statistical significance of differences in lung tumorigenesis between BRaf CA versus KRas LSL mice was assessed using the exact Wilcoxon rank-sum test (27) .
At 6 weeks, the lungs of Ad-Cre-treated BRaf CA or KRas LSL mice had a similar percentage of epithelial hyperplasia (9% and 12.5%, respectively, P ¼ 0.23; Fig. 1C ). The majority of lesions in BRaf CA mice ($74%) were fully formed, low-grade adenomas, compared with only 5% of such lesions in the KRas LSL mice (P ¼ 0.002). Indeed, at 6 weeks, the vast majority of the lesions in the KRas LSL mice (85%) were adenomatous hyperplasias compared with only 17% of such lesions in BRaf CA mice (P ¼ 0.04).
At 17 weeks, there was no significant difference in the percentage of epithelial hyperplasias between BRaf CA and KRas LSL mice, (1.3% vs. 4%, respectively, P ¼ 0.52). Adenomatous hyperplasias were more prevalent in KRas LSL mice than in BRaf CA mice (30% vs. 11% respectively, P ¼ 0.0005). The percentage of low-grade adenomas remained significantly higher in BRaf CA mice than in KRas LSL mice (88% vs. 56% respectively, P ¼ 0.002). Importantly, high-grade adenomas were only observed in KRas LSL mice, where they comprised 10% of the total observable lung lesions (P ¼ 0.02; Fig. 1C ).
The majority of BRAF V600E -induced lung tumors appeared benign and adenomatous with a structured papillary pattern made up of seemingly well-differentiated, cuboidal epithelial cells and lacking characteristics of high-grade tumors (Fig. 1A , bottom). These observations are in accordance with our previous studies showing the benign nature of BRAF V600E -induced lung tumors and their low rate of spontaneous malignant progression (18) . In contrast, despite the overall lower tumor burden, approximately 10% of lung tumors in KRas LSL mice appeared to be of higher grade, as evidenced by nuclear atypia, such as prominent nucleoli and an increased nucleus to cytoplasm ratio (Fig. 1A, bottom) . Finally, we observed no evidence of either local invasion, pleural effusion, or distant metastatic spread in lung tumors arising in either BRaf CA or KRas LSL mice, which is consistent with our previous observations and those of others (17, 18, 20) .
To determine whether there was a difference in proliferation rate of KRAS G12D -versus BRAF V600E -induced lung tumors, 17 weeks after initiation, appropriate mice were injected with BrdUrd approximately 20 hours before euthanasia. Lung sections were stained with antibodies against BrdUrd and SP-C, a marker for alveolar type 2 pneumocytes expressed in KRAS G12D -and BRAF V600E -induced lung tumor cells (17, 18) . Tumor cell-specific proliferation was assessed by measuring the percentage of SP-C-positive cells that also stained for BrdUrd incorporation by double label immunofluorescence. By these criteria, 0.98% of BRAF V600E -expressing and 1.67% of KRAS G12D -expressing tumor cells were BrdUrdpositive, respectively (P ¼ 0.12, Fig. 2 ). These data were confirmed by double label immunofluorescence for Ki67/SP-C double-positive cells. By these criteria, 2.35% of BRAF V600E -expressing and 4.53% of KRAS G12D -expressing tumor cells were Ki67/SP-C double-positive (P ¼ 0.08, Fig.  2B ). Hence, at 17 weeks, KRAS G12D -and BRAF V600E -expressing tumors display a relatively low proliferative index and, although there was a trend to a higher proliferative index in KRAS G12D -induced tumors, this did not reach statistical significance.
We next assessed signal pathway activation downstream of oncogenic KRAS G12D or BRAF V600E by immunohistochemical staining for phospho-ERK1/2 (pERK1/2) or phospho-S6 (pS6) in low-or high-grade adenomas. In general, the levels of pERK1/2 and pS6 were low but detectable in both BRAF V600E -and KRAS G12D -induced low-grade adenomas. However, we did not detect a substantial elevation in pERK1/2 in KRAS G12D -induced high-grade adenomas, although elevated pS6 was detected in these tumors (Fig. 3) . These data are consistent with the previous observations that neither KRAS G12D nor BRAF V600E induce high-level signal pathway activation during the early stages of lung tumorigenesis (22) .
BRAF
V600E -and KRAS G12D -induced lung tumors express markers of alveolar type 1 and 2 pneumocytes
To further characterize lung tumors arising in Ad-Cretreated BRaf CA or KRas LSL mice, we stained for expression of markers of epithelial cells of the terminal bronchioles and alveoli: Clara cell antigen (CCA); SP-C, and aquaporin 5 (AQP5). Clara cells are CCA-positive but negative for SP-C and AQP5. Alveolar type 2 (AT2) pneumocytes are SP-C-positive but negative for CCA and AQP5. Alveolar type 1 (AT1) pneumocytes are AQP5-positive but negative for CCA and SP-C. As previously reported, adenomas arising in both the BRaf CA and KRas LSL mice were largely CCA-negative (data not shown). Interestingly, both BRAF V600E -and KRAS G12D -induced lung tumors were positive for both SP-C and AQP5, a combination of marker expression not readily detected in the normal mouse lung epithelium. SP-C was localized in a punctate manner inside tumor cells consistent with its sequestration into lamellar bodies that are characteristic of AT2 cells (28) . AQP5, an integral membrane water channel, appeared membranous and expressed asymmetrically on tumor cells consistent with its normal expression on the apical surface of AT1 cells ( Fig. 4A;  ref. 29) .
To rule out the possibility that the apparent double positivity of lung tumor cells for both SP-C and AQP5 was not simply due to the close juxtaposition of 2 different cell types, we analyzed BRAF V600E -induced lung tumors by electron microscopy. This analysis revealed that BRAF V600E -induced tumors were composed of cuboidal AT2-like cells with prominent lamellar bodies (Fig. 4B , arrowed) and were not infiltrated by normal AT1-like cells. To further analyze the extent of tumor cell expression of AT1 markers, we stained for RAGE (receptor for advanced glycosylation end products) and podoplanin. However, neither BRAF V600E -nor KRAS G12D -induced lung tumors expressed these proteins (data not shown). To test whether the combination of SP-C and AQP5 expression is observed in human lung cancer, we stained sections of 8 lung cancers with documented BRAF mutation with antisera (30) . However, human lung cancer cells in these sections were uniformly negative for the expression of these proteins (data not shown).
To allay concerns about the specificity of the anti-AQP5 antibody and to test for a possible role of AQP5 in lung tumorigenesis, we generated BRaf CA mice homozygous for a null allele of Aqp5 (23 (24) . Ad-Cre infection of the lung epithelium of these mice initiates oncogenic BRAF V600E expression and the expression of luciferase, which can be used to image tumorigenesis and response to pathwaytargeted therapy using a Xenogen In Vivo Imaging Systems (IVIS).
Bioluminescence (in p/s) was measured in compound BRaf CA ;LucRep mice at different times after initiation with Ad-Cre (10 7 pfu). Baseline signal was determined to be 2 Â 10 6 p/s by measuring bioluminescence from Ad-Creinfected LucRep littermates lacking the Cre-activated BRaf CA allele. Starting 5 weeks after Ad-Cre infection, bioluminescence in the lung was observed to increase in a representative BRaf CA ;LucRep mouse and at 9 weeks had increased 30-fold to 6 Â 10 7 p/s (Fig. 5) . At this time, PD0325901 was administered orally for 5 weeks on a 5-d/wk dosing schedule. Over this period, the luciferase signal gradually decreased until it was below baseline (Fig. 5 ). In addition, at the time of drug administration, this mouse appeared hunched, had lost body weight, and was displaying the signs of respiratory distress that typify the end stage of confluent BRAF V600E -induced benign lung tumorigenesis. Following 5 weeks of drug treatment, the mouse appeared healthy, had gained 8.7 grams in body weight ($40% increase), and no longer displayed signs of respiratory distress. Upon euthanasia of similarly treated BRaf CA mice, we could find little or no evidence of residual tumors following 5 weeks of MEK1/2 inhibition (data not shown). This experiment was repeated with an additional group of 5 BRaf CA ;LucRep mice, all of which displayed robust tumor regression and health status improvements in response to MEK1/2 inhibition (data not shown). Despite the profound tumor regression, cessation of MEK1/2 inhibitor administration led to rapid regrowth of lung tumors in all the mice. These data indicate that MEK!ERK signaling is required for both initiation and maintenance of BRAF V600E -induced lung tumors. However, To assess the effect of MEK1/2 inhibition on KRAS G12D -induced lung tumorigenesis, a cohort of KRas LSL mice was initiated by infection with Ad-Cre, and 4 weeks later, a time before the onset of tumorigenesis (Fig. 1 ), mice were treated with either vehicle or PD0325901 for 6 weeks at which time they were euthanized and lung tumor burden assessed (Fig. 6A compares vehicle vs. PD325901 -PD901). MEK1/2 inhibition with PD0325901 treatment was highly effective in the prevention of KRAS G12D -driven lung tumors (Fig. 6A) . Whereas vehicle-treated mice had 12.5 tumors per lung section, PD0325901-treated mice had an average of 1.4 lung tumors per section-a 9-fold decrease in lung tumor incidence (P ¼ 0.0012; Fig. 6A ). In addition, we observed a 9-fold difference in the size of individual lesions when comparing control versus PD0325901-treated mice (69,354 mm 2 in vehicle-treated mice compared with 7.837 mm 2 for drug-treated mice, P ¼ 0.0002; Fig.  6A ). The differences in tumor number and size contributed to an overall 47-fold lower tumor burden in PD0325901-treated mice than in vehicle-treated littermates (3.4% vs. 0.072%, P ¼ 0.0005; Fig. 6A ). These data indicate that RAF!MEK!ERK signaling is essential for the onset of KRAS G12D -induced lung tumorigenesis.
Next, we assessed the efficacy of PD0325901 in promoting regression of preexisting KRAS G12D -initiated lung tumors. Ten weeks after initiating KRAS G12D expression, mice were treated with either vehicle or PD0325901 for a further 6 weeks at which time they were euthanized and lung tumor burden assessed -driven lung tumors. A, KRas LSL/þ mice were initiated with 10 7 pfu Ad-Cre and then 4 weeks later administered with 12.5 mg/kg PD0325901 dosed 5 times a week for 6 weeks. Lung tumor number, size, and overall tumor burden were calculated as described previously. Representative H&E-stained lung tumor sections from vehicle-treated (vehicle-P) or PD0325901-treated (PD0325901-P) mice are presented. Bar, 500 mm. B, KRas LSL/þ mice were initiated with 10 7 pfu Ad-Cre and then 10 weeks later administered with 12.5 mg/kg of PD0325901 dosed 5 times a week for 6 weeks. Lung tumor number, size, and overall tumor burden were calculated as described previously. Representative H&E-stained lung tumor sections from vehicle-treated (vehicle-T) or PD0325901-treated (PD0325901-T) mice are presented. Residual lung tumor after PD0325901 treatment is boxed. Bar, 500 mm. C, luciferase imaging of KRas LSL/þ and KRas þ/þ luciferase reporter mice following infection with 10 8 pfu Ad-Cre. Mice were administered with 12.5 mg/kg PD0325901 at 11.5 weeks after infection and dosed 5 days a week for 7.5 weeks. Bioluminescent signal was measured in p/s. (Fig. 6B compares vehicle vs. PD325901 -PD901 ). Mice treated with PD0325901 showed significantly fewer tumors per lung section than vehicle-treated littermates (7.6 vs. 25.3, P ¼ 0.01). Moreover, whereas vehicle-treated mice displayed mostly high-grade lung adenomas, lesions in PD0325901-treated mice were predominantly epithelial or adenomatous hyperplasias and thus generally smaller than tumors observed in vehicletreated mice. However, the difference in overall lesion size between PD0325901-and vehicle-treated mice was not significant (129,679 vs. 305,584 mm 2 , P ¼ 0.08). This is likely due to the presence of residual large adenomas (Fig. 6B, PD325901 -T boxed) remaining after the full course of drug treatment, which were presumably resistant to the effects of MEK inhibition. Importantly, overall tumor burden was decreased approximately 8-fold in PD0325901-treated KRas LSL mice compared with control (19% compared with 2.2%, P ¼ 0.0002; Fig. 6B ).
To unequivocally show regression of preexisting KRAS G12D -induced lung tumors, we initiated tumorigenesis in a representative KRas LSL ;LucRep mouse and monitored tumor growth by bioluminescent imaging as described above (Fig. 6C) . Baseline signal (2.6 Â 10 6 p/s) was determined as the average signal of KRas þ/þ ;LucRep mice treated with the same dose (10 8 pfu) of Ad-Cre. This KRas LSL/þ ;LucRep mouse displayed a consistent bioluminescent signal approximately 17-fold above baseline 11.5 weeks after initiation of KRAS G12D expression, at which time PD0325901 was administered. After 8.5 weeks of PD0325901 treatment, the bioluminescent signal from lung tumor burden was reduced approximately 6-fold (4.5 Â 10 7 -8 Â 10 6 p/s), consistent with the reduction in tumor burden assessed by histochemical analysis of lung sections (Fig. 6B) . However, unlike the situation with BRAF V600E -induced lung tumors, MEK1/2 inhibition did not result in the reduction of the bioluminescent signal to baseline. Moreover, as with BRAF V600E -induced lung tumors, cessation of PD0325901 administration led to rapid regrowth of KRAS G12D -expressing lung tumors requiring that this mouse be euthanized 2 weeks later (Fig. 6C) . Cumulatively, these data provide compelling evidence that inhibition of RAF!MEK!ERK signaling both prevents the growth and promotes the regression of preexisting of KRAS G12D -induced lung tumors. However, the presence of adenomas at the end of the drug treatment period may explain the incomplete tumor regression observed in KRas LSL mice and, thus, why KRAS G12D -driven lung tumors appear less sensitive to MEK1/2 inhibition than their BRAF V600E -expressing counterparts.
V600E -or KRAS G12D -expressing lung tumor-derived cell lines are sensitive to MEK inhibition in vitro
The antitumor effects of PD0325901 against BRAF
V600E
-or KRAS G12D -induced tumors in vivo could be mediated either by tumor cell autonomous or nonautonomous mechanisms or some combination thereof. Hence, to determine whether there is a tumor cell autonomous response to MEK inhibition, we used cell lines isolated from either BRAF (Fig. 7B) , consistent with the observed inhibition of cell proliferation. In parallel, vehicle versus PD0325901-treated cells were stained for a marker of apoptosis (Annexin-V) and cell death (propidium iodide; PI). Whereas there was a modest increase of apoptotic and dead cells in PD0325901-treated cultures, the majority of cells remained Annexin-V-and PI-negative (data not shown).
In parallel, cell extracts were analyzed to assess the effect of MEK inhibition on signal pathway activation. As expected, PD0325901 treatment led to increased phospho-MEK1/2 but decreased phospho-ERK1/2, consistent with the mechanism of action of this agent (Fig. 7C) . Both cell lines also displayed decreased expression of cyclin D1, consistent with the known role of ERK1/2 signaling in cyclin D1 regulation (34) . We also detected modest induction of the proapoptotic BCL-2 family member BIM, consistent with its regulation by ERK signaling (35) , and the presence of cleaved caspase-3 in PD0325901-treated cells. Cumulatively, these data suggest that the antitumor effect of PD0325901 in mouse models of KRAS G12D -or BRAF V600E -induced lung tumorigenesis results, at least in part, from direct antiproliferative effects of the agent on tumor cells mediated by cell-cycle arrest and accompanied by a modest induction of apoptosis.
Discussion
Mutationally activated KRAS is a feature common to approximately 25% of all cancers and is particularly prevalent in pancreas, colon, and lung cancer (2, 3, 36) . Consistent with its documented importance in human lung cancer, expression of oncogenic KRAS G12D in the mouse lung epithelium leads to the development of non-small cell adenocarcinomas, some of which have a propensity for metastasis (17, 20, 21) . However, it remains unclear, which of its various effector pathways are critical for KRAS G12D -induced lung tumor initiation and maintenance. Here, we show that RAF!MEK!ERK signaling is both necessary and sufficient for the early stages of KRAS G12D -induced tumorigenesis up to the formation of low-grade adenomas. Consistent with this, expression of oncogenic BRAF V600E in the lung epithelium leads to development of benign lung tumors with most of the same histologic and morphologic features but with strikingly enhanced efficiency compared with KRAS G12D . One explanation for this difference may be the efficiency of Cre-mediated recombination of the conditional BRaf CA and KRas LSL alleles, which is not readily measurable in the lung epithelium. Another possibility is that there may be more cells with tumorigenic potential that express BRAF compared with KRAS. Finally, the efficiency of lung tumorigenesis may reflect a better ability of BRAF V600E to elevate MEK!ERK signaling compared with KRAS G12D . Although we did not see a difference in pERK between KRAS G12D -or BRAF
V600E
-induced lung tumors, we were not able to assess pERK levels in single initiated cells to determine whether there may be differences between the 2 oncogenes in signal pathway engagement. Although this highly reproducible difference in the efficiency of BRAF V600E -versus KRAS G12D -induced lung tumorigenesis was surprising, it is not without precedent. For example, whereas BRAF V600E elicits papillary thyroid cancer when expressed in mouse thyrocytes, KRAS G12D expression had no effect in the thyroid unless combined with PTEN silencing (37, 38) .
Although BRAF V600E elicits abundant lung tumors at early time points, they remain low-grade, benign and rarely progress to lung cancer (18) . In contrast, despite the overall reduced efficiency of lung tumorigenesis, KRas LSL mice invariably develop high-grade tumors with a strong propensity for further malignant progression (17) . Whereas evidence suggests that high-grade lesions emerge from more benign tumors, it remains possible that these lesions emerge from a different cell of origin (17, 22) . To explore the possibility that KRAS G12D -or BRAF V600E -induced lung tumors may display phenotypic differences reflective of their cell of origin, we stained tumors for markers of cells of the distal lung epithelium. Whereas both KRAS G12D -and BRAF
-induced lung tumors types lacked CCA expression, they were uniformly double-positive for SP-C and AQP5, markers of AT2 and AT1 pneumocytes, respectively, and a combination of markers not detected in normal lung. However, by most other criteria, KRAS G12D -and BRAF 
KRAS
G12D to promote malignant progression at late time points may be a result of differences in signaling caused by this oncogene perhaps reflected by the elevated phospho-S6 detected in high-grade KRAS G12D -induced tumors. Finally, It has been proposed that the cell of origin of KRAS G12D -driven lung tumors is a bronchioalveolar stem cell (BASC), which coexpresses both CCA and SP-C (39). Although we detected small numbers of double CCA/SP-C-positive cells in BRAF V600E -driven tumors, not all tumors contained such cells and their frequency was less than 1% of the total tumor cells (data not shown).
To explore the importance of MEK!ERK signaling in BRAF V600E -or KRAS G12D -driven tumors, we used PD0325901, a highly selective and potent inhibitor of MEK1/2 (31, 32) . In vivo bioluminescent imaging showed the ability of this agent, not only to prevent the onset of BRAF V600E -induced tumorigenesis (18) but also to promote dramatic regression of preexisting lung tumors. PD0325901 treatment also effectively prevented the formation of KRAS G12D -driven tumors and promoted the regression of preexisting lung tumors, consistent with the work of others (33, 40) . However, the magnitude of tumor regression in the KRas LSL mice was less dramatic than that observed in BRaf CA mice and, at euthanasia, we detected fully formed adenomas in the lungs of PD0325901-treated KRas LSL mice, which were presumably resistant to the cytotoxic effects of MEK inhibition. In addition, despite the striking effects of MEK1/2 inhibition on BRAF
V600E
-induced lung tumorigenesis, we were unable to eradicate tumor-initiating cells from the lungs of these animals, which rapidly regrew lung tumors upon cessation of drug treatment. The reasons for these observations are the subject of ongoing investigation.
Tumor cell autonomous effects of MEK1/2 inhibition were established using cultured cells isolated from BRAF V600E -or KRAS G12D -driven lung tumors. Interestingly, although such cell lines were sensitive to the antiproliferative effects of MEK inhibition and displayed some evidence of apoptosis, we did not observe substantial involution of these cell cultures. This leaves open the possibility that MEK1/2 inhibition has both tumor cell autonomous and nonautonomous effects that contribute to the regression of BRAF V600E -and KRAS G12D -induced lung tumors in vivo. However, these data emphasize the central importance of RAF!MEK!ERK signaling in KRAS G12D -induced lung tumorigenesis in the mouse. Because mutationally activated KRAS remains an intractable pharmacologic target, it is possible that targeting MEK1/2, either alone or in combination chemotherapy, may represent a viable approach for targeting KRAS-induced lung cancer (11) . 
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